Aygestin
(norethindrone)ApprovedSmall molecule
TevaNorethindrone is a hormone medication used to treat endometriosis (tissue growth causing pain and irregular bleeding), abnormal menstrual periods, and to restore normal menstrual cycles in women who have stopped menstruating. It works by preventing the uterine lining from growing and regulating hormone production.[2] Aygestin is currently approved and in use across 3 indications[4].[1]
Aygestin is one of 89 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Approved.
3
Indications
8
Total Trials
1
Active Trials
88
Competitors
5
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
566 competitors in Hypertension
#DrugCompanyPhaseTrials
1Aygestin
TevaApproved
Edarbi
TakedaPreclinical
Benicar
NovartisPreclinical
Winrevair
Merck & Co.Preclinical
Alphagan
AbbViePreclinical
Avastin
BBio-Thera Solutions
Preclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Cecon
MMcGuff Pharmaceuticals, Inc.
Preclinical
Vivarin
HHikma Pharmaceuticals LLC
Preclinical
Inderal
Mylan Pharmaceuticals IncPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Systemic Lupus Erythematosus1 trial
Tics1 trial
3 more indications
Regulatory
FDA Approval Timeline[5]
Jan 1, 1982
NORLUTATE
NDA NDA012184
Jan 1, 1982
NORLUTIN
NDA NDA010895
Jan 1, 1982
MICRONOR
NDA NDA016954
Jan 1, 1982
NOR-QD
NDA NDA017060
Apr 21, 1982
AYGESTIN
NDA NDA018405
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Aygestin drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for norethindrone. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]